Sino Biopharmaceutical

Sino Biopharmaceutical - specializes in the manufacture of generics and biosimilars for the treatment of hepatitis, tumors, ophthalmia and cardiovascular diseases, as well as the release of analgesics.

Performance indicators

2021

The company's revenue growth in 2021 amounted to 14% YoY, while a year earlier it was recorded a drop of 2%. The main driver of the company's revenue growth was the segment of drugs for the treatment of oncology. Gross margin dynamics improved YoY by 2 pp (from 78% in 2020 to 80% in 2021). Profit at the end of the year increased from 4.3 billion yuan to 16.6 billion yuan.

However, the main profit growth was due to the revaluation of investments in Sinovac, which brought the company 13.6 billion yuan. The company made these investments in December 2020, acquiring a 15% stake in the company. Thus, paper profit from revaluation of investments in 2021 amounted to 13.6 billion yuan. Excluding this revaluation, net profit in annual terms decreased by 30%.

In terms of segments, revenue from the portfolio of respiratory drugs increased by 92%. The segment of drugs for the treatment of oncology provided a revenue increase of 21%. Revenue from the Orthopedics segment increased by 18% YoY. Sales of hepatitis C drugs decreased by 2.5% YoY.

At this time, the company is among the 200 largest public companies in China.